You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
News items for the in vitro diagnostics industry for the week of April 27, 2020.
Policymakers have touted such tests as key to easing shutdowns, but high specificity will be needed to avoid misinforming people about their infection status.
The kit is designed for the qualitative detection of nucleic acid from SARS-CoV-2 nasal, nasopharyngeal, and oropharyngeal swab samples.
The test, run on the BD Max system, allows hospitals to diagnose SARS-CoV-2 on site and receive results in less than three hours.
The point-of-care test is designed to detect SARS-CoV-2 antibodies in blood, serum, or plasma, with results available within 15 minutes.
The firms are developing a testing system that involves drawing fingertip blood and doing routine testing in Babson's CLIA-certified laboratory.
A number of manufacturers say that the shortage of swabs and transport media for facilitating SARS-CoV-2 testing that clinicians are facing will soon abate.
The joint submission of the coronavirus assay is part of a long-standing collaboration between the two firms to put BioGX assays on the BD Max system.
In announcing a national emergency on Friday, Trump paraded out executives from the private sector as the administration tries to increase testing capacity
The test is for use with BD's BD Max fully-automated system and processes 24 samples in less than three hours.